HIF Triplet (MK6482 + Pembrolizumab + Lenvatinib), CTLA4 Triplet (MK1308A + Lenvatinib), Pembrolizumab/lenvatinib

Biodrugs/ Drugs
Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
3Phase III in Spain, 2Phase II, 1Phase I